Ginkgo Bioworks Holdings

Ginkgo Bioworks Holdings, Inc. is a biotech company. Its platform is market agnostic and enables biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. It operates through the Cell Programming/Foundry, and Biosecurity segments. The company was founded by Jason Kelly, Reshma Shetty, Bartholomew Canton, Austin Che, and Thomas F. Knight, Jr. in 2008 and is headquartered in Boston, MA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Ginkgo Bioworks reports strong Q4 earnings, eyes biopharma growth

Ginkgo Bioworks reports strong financial performance and strategic growth in Q4 2022, focusing on downstream value share and biosecurity leadership.
While facing challenges with negative EBITDA, the company aims to drive efficiency, expand biosecurity initiatives, and capitalize on opportunities in biopharma and API manufacturing.
With a solid financial foundation, Ginkgo is well-positioned to leverage its expertise in programming cells and proprietary protein sequences for future growth and market expansion.

Ginkgo Bioworks reports strong Q1 growth and eyes global expansion

Ginkgo Bioworks showcased strong performance in Cell Engineering and Biosecurity revenue, emphasizing platform improvement and strategic partnerships.
While facing challenges in enterprise sales and operating expenses, the company is well-positioned for growth through international biosecurity expansion and biopharma focus.
Opportunities lie in global biosecurity initiatives, biopharma sales pipeline, and persistent monitoring programs, signaling a promising future for Ginkgo.

Ginkgo Bioworks posts robust Q2 results, eyes revenue diversification

Ginkgo Bioworks reported strong growth in revenue and active programs, with a focus on operational efficiencies and customer relationships.
Transitioning to success-based pricing models and task-specific data training positions the company for revenue diversification and enhanced customer value.
While facing market challenges and funding constraints, Ginkgo is strategically expanding its offerings and driving towards profitability through operational enhancements.

Ginkgo Bioworks reports strong Q3 performance and biosecurity opportunities

Ginkgo Bioworks reports strong performance with revenue growth and increased active programs.
The company's strengths lie in AI progress, diverse customer base, and biosecurity applications.
Challenges include deal timing, competitive positioning, and managing operational expenses.
Opportunities include tech licensing deals, AI-driven efficiency, and synergies between biosecurity and cell engineering.

Ginkgo Bioworks navigates revenue challenges with strategic growth initiatives

Ginkgo Bioworks faces revenue challenges from program dynamics but is strategically positioned for growth through R&D investments and partnerships.
The company's focus on innovation, efficiency, and biosecurity infrastructure underscores its commitment to leading in biotech R&D.
Opportunities in expanding partnerships, enhancing automation technology, and standardizing interfaces signal a promising path for Ginkgo's future growth.
Despite short-term revenue setbacks, Ginkgo's strategic initiatives and industry positioning bode well for long-term success and market leadership.

Ginkgo Bioworks targets EBITDA breakeven by 2026 amid revenue challenges

Ginkgo Bioworks is navigating challenges in revenue growth while focusing on cost reductions and operational efficiency to achieve EBITDA breakeven by 2026.
The company's strategic shift towards biopharma and bioAg sectors showcases flexibility and growth potential in serving large companies with research budgets.
Introduction of 'Lab Data as a Service' and focus on streamlining workflows present opportunities for scalability and revenue enhancement.
Despite challenges in revenue outlook and restructuring efforts, Ginkgo remains committed to operational success and financial sustainability.

Ginkgo Bioworks advances cost-saving goals amidst revenue challenges

Ginkgo Bioworks progresses towards financial targets amidst revenue challenges and aggressive cost-saving measures.
Strategic focus on automation, biosecurity, and revenue diversification positions the company for future growth.
Challenges include revenue decline, employee impact from layoffs, and balancing cost reduction with innovation.
Opportunities lie in new revenue streams, margin accretive initiatives, and market differentiation through mission-driven approach.

Ginkgo Bioworks reports mixed Q3 results, focuses on growth strategies

Ginkgo Bioworks showed strength in cost-cutting, revenue generation, and strategic focus, despite a negative adjusted EBITDA.
Challenges include financial pressures, margin concerns, and potential risks in resource utilization and funding stability.
Opportunities lie in new offerings, AI capabilities, market expansion, and revenue scale for improved profitability.
Management's emphasis on cost reduction, revenue growth, and innovation positions the company for long-term success and sustainability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

You might want to make a small investment now, while the stock is trading under $4 a share.

Ginkgo Bioworks Is Chasing a $4 Trillion Opportunity

BOSTON , June 7, 2022 /PRNewswire/ --  Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced a collaboration with Novo Nordisk , a leading global healthcare company, to create novel expression hosts for pharmaceutical products. Today, hundreds of millions of people are living with diabetes, obesity, and other serious chronic diseases, putting a strain on individuals, families, and healthcare systems.

Ginkgo Bioworks and Novo Nordisk to Collaborate on Expression Systems for Pharmaceutical Products

Through real-time metabolite monitoring, Bitome's technology is expected to support accelerated product development timelines across Ginkgo's portfolio of cell programs BOSTON , June 6, 2022 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced that it has acquired certain assets from Bitome, a company pioneering real-time metabolite monitoring for faster biological product development. Bitome has developed technology leveraging machine learning to provide continuous monitoring of cell culture media, illuminating the performance of cells in real-time and enabling faster rates of bioprocess optimization.

Ginkgo Bioworks Acquires Bitome, an Integrated Metabolite Monitoring Platform

Camber Energy

Imperial Petroleum

Which penny stocks are you watching right now? The post Top Penny Stocks to Watch in Early June 2022  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Top Penny Stocks to Watch in Early June 2022

BOSTON , June 2, 2022 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, announced today that management is scheduled to participate in William Blair's 42nd Annual Growth Stock Conference, on June 9, 2022, at 11:20 a.m. CT. Further details, a webcast link, and a replay of the presentation, if available, will be posted on the company's investor relations website at https://investors.ginkgobioworks.com/events.

Ginkgo Bioworks Announces Participation in William Blair's 42nd Annual Growth Stock Conference

Coinbase

Zoom Video

These stocks are all down more than 70% from their 52-week highs.

3 Beaten-Down Cathie Wood Stocks That Look Like Bargains

Didi Global

Oncternal Therapeutics Inc

Here are three penny stocks to add to your watchlist right now The post Hot Penny Stocks to Watch as May Ends  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Hot Penny Stocks to Watch as May Ends

Elevation Oncology

Check these penny stocks out for your watchlist The post Best Penny Stocks to Buy as May Ends? 3 to Watch Right Now  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks to Buy as May Ends? 3 to Watch Right Now

Eos Energy Enterprises

FTC Solar

Porch Group

Best penny stocks to buy according to analysts. The post Best Penny Stocks To Buy According To 4 Analysts & Targets Up To $8 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks To Buy According To 4 Analysts & Targets Up To $8

Amyris

Which of these fallen stocks has the best chance of recovery?

Better Buy: Gingko Bioworks vs. Amyris

Shares of DNA stock are in focus following Ark Invest's buying spree this month. In the past two days, Ark has purchased 4.5 million shares.

Cathie Wood Keeps Buying Gingko Bioworks (DNA) Stock

IAMGOLD

Kinross Gold

Can penny stocks show positive momentum in May? The post Why These Penny Stocks Climbed on May 19th, 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Why These Penny Stocks Climbed on May 19th, 2022

DNA stock is a falling knife in 2022, and the latest earnings do not justify being optimistic about reaching profitability soon. The post Losing Money Is in Ginkgo Bioworks Holdings' DNA appeared first on InvestorPlace.

Losing Money Is in Ginkgo Bioworks Holdings' DNA

Partnership recognizes the importance of global cooperation to prevent and respond to pandemics By leveraging Ginkgo's large-scale biosecurity platform and Qatar's pioneering investments in biotechnology, collaboration aims to build new biosecurity capabilities and accelerate the establishment of a global pathogen monitoring network BOSTON and DOHA, Qatar , May 18, 2022 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, and First Serv, a Qatari investment holding company, today announced that they have entered into a non-binding Memorandum of Understanding (MOU) to develop and implement new biosecurity capabilities in Qatar. The partners to the MOU recognize the importance of international collaboration and cooperation to effectively prevent and respond to biological threats in this global age.

Ginkgo Bioworks and First Serv Announce Plans to Develop and Implement Innovative Global Biosecurity Capabilities in Qatar

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA ) Q1 2022 Earnings Conference Call May 16, 2022 4:30 PM ET Company Participants Anna Marie Wagner - SVP of Corporate Development Jason Kelly - Co-Founder & CEO Mark Dmytruk - CFO Conference Call Participants Matt Sykes - Goldman Sachs Tejas Savant - Morgan Stanley Rahul Sarugaser - Raymond James Mark Massaro - BTIG Steve Mah - Cowen Derik De Bruin - Bank of America Anna Marie Wagner Good afternoon. This is Anna Marie Wagner, SVP of Corporate Development at Ginkgo Bioworks.

Ginkgo Bioworks Holdings, Inc. (DNA) CEO Jason Kelly on Q1 2022 Results - Earnings Call Transcript

Ginkgo Bioworks Holdings Inc (NYSE: DNA) shares are trading lower in Monday's after-hours session after the company reported financial results. Ginkgo Bioworks said first-quarter revenue increased 282% year-over-year to $168 million, which beat the $105.68-million estimate, according.

Why Ginkgo Bioworks Stock Is Falling After Hours

$168 million of Total revenue in Q1 2022, representing an increase of 282% over Q1 2021 11 new Cell Programs added in Q1 2022, representing 175% growth over Q1 2021 Increasing full year guidance for Total revenue from $325  – $340 million to $375 – $390 million, reiterating Foundry revenue guidance and increasing Biosecurity revenue guidance Recently announced plans to expand platform capabilities in agricultural biologicals through a series of M&A transactions and flagship collaboration with Bayer $1.5 billion cash balance provides meaningful multi-year runway as we drive towards profitability BOSTON , May 16, 2022 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), the leading horizontal platform for cell programming, today announced its results for the first quarter ended March 31, 2022. The update, including a webcast slide presentation with additional details on the first quarter and supplemental financial information, will be available at investors.ginkgobioworks.com.

Ginkgo Bioworks Reports First Quarter 2022 Financial Results

Nu Holdings

Vroom

Here's what you need to know about trading penny stocks on May 16th The post What to Know About Buying Penny Stocks on May 16th  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

What to Know About Buying Penny Stocks on May 16th

Hycroft Mining Holding Corporation

Penny Stocks to Buy? Here are a few for your watch list.

Penny Stocks To Buy In May? 3 To Watch Before Next Week

Adaptive Biotechnologies

BridgeBio Pharma Inc

FuboTV

Himax Tech

Microsoft

Because of this stock market crash, some wonderful stocks are super cheap in 2022. Here's a mini-portfolio of innovative companies trading under $10 a share right now.

10 Amazing Stocks Under $10 (Part II)

These are stocks that could make for great long-term investments.

2 Promising Growth Stocks That Are Down 70% From Their Highs

Ginkgo's animal-free eggs deal with Evo food could be just what its overlooked stock needed to reach its full potential. DNA stock is a buy.

Ginkgo Bioworks' Animal-Free Eggs Make DNA Stock Enticing

Evo Foods will leverage Ginkgo's cell engineering capabilities to explore recombinant production methods for egg proteins PALO ALTO, Calif. and BOSTON , May 11, 2022 /PRNewswire/ -- Evo Foods , a consumer packaged goods company creating the next generation of plant-based substitutes for animal products, and Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced a partnership to develop a method for producing animal-free egg proteins for use in Evo's products.

Evo Foods and Ginkgo Bioworks Announce Partnership to Develop Animal-Free Egg Products

Presentation and Q&A session scheduled for post-market on Monday, May 16, 2022 BOSTON , May 9, 2022 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, announced today that it plans to host a presentation and Q&A session reviewing business performance for the first quarter ended March 31, 2022, on Monday, May 16, 2022, beginning at 4:30 p.m. ET. The presentation details and webcast link will be available on Ginkgo's investor relations website at https://investors.ginkgobioworks.com , and a replay will be made available.

Ginkgo Bioworks Announces Date of First Quarter 2022 Results Presentation

Which penny stocks are you watching right now? The post Check These 3 Hot Penny Stocks Out For Your Watchlist  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

News for Ginkgo Bioworks Holdings Stock (DNA)